Abstract
With the sudden outbreak of COVID-19 patient worldwide and associated mortality, it is critical to come up with an effective treatment against SARS-CoV-2. Studies suggest that mortality due to COVID 19 is mainly attributed to the hyper inflammatory response leading to cytokine storm and ARDS in infected patients. Sphingosine-1-phosphate receptor 1 (S1PR1) analogs, AAL-R and RP-002, have earlier provided in-vivo protection from the pathophysiological response during H1N1 influenza infection and improved mortality. Recently, it was shown that the treatment with sphingosine-1-phosphate receptor 1 analog, CYM5442, resulted in the significant dampening of the immune response upon H1N1 challenge in mice and improved survival of H1N1 infected mice in combination with an antiviral drug, oseltamivir. Hence, here we suggest to investigate the possible utility of using S1P analogs to treat COVID-19.
References
Aug 19, 2007·PLoS Pathogens·Anna de LangMichael G Katze
Mar 25, 2009·International Journal of Immunopathology and Pharmacology·M SaliM Fraziano
Nov 13, 2009·Journal of Virology·Jun ChenKanta Subbarao
Jul 1, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kevin B WalshMichael B A Oldstone
Sep 20, 2011·Cell·John R TeijaroHugh Rosen
Sep 26, 2013·The Journal of Infectious Diseases·Jie ZhouKwok-Yung Yuen
Mar 29, 2014·Journal of Virology·Kevin B WalshMichael B A Oldstone
Jul 21, 2015·Cellular & Molecular Immunology·Qiang LiuZhan-qiu Yang
Oct 13, 2015·Drug Discovery Today·Mohd ArishAbdur Rub
Jan 21, 2016·Proceedings of the National Academy of Sciences of the United States of America·John R TeijaroHugh Rosen
Feb 13, 2016·Cell Host & Microbe·Rudragouda ChannappanavarStanley Perlman
Dec 31, 2016·Biomolecules & Therapeutics·Soo-Jin Park, Dong-Soon Im
Mar 30, 2017·Frontiers in Immunology·Sabira Mohammed, K B Harikumar
May 4, 2017·Seminars in Immunopathology·Rudragouda Channappanavar, Stanley Perlman
Nov 22, 2017·American Journal of Respiratory and Critical Care Medicine·Yaseen M ArabiUNKNOWN Saudi Critical Care Trial Group
Aug 18, 2018·PLoS Neglected Tropical Diseases·Mohd ArishAbdur Rub
Mar 29, 2019·Scientific Reports·Jiangnan ZhaoYi Shi
Jan 28, 2020·Lancet·Chaolin HuangBin Cao
Feb 3, 2020·Lancet·Nanshan ChenLi Zhang
Feb 9, 2020·Lancet·Alimuddin ZumlaMarkus Maeurer
Feb 23, 2020·The Lancet. Respiratory Medicine·Zhe XuFu-Sheng Wang
Mar 14, 2020·JAMA Internal Medicine·Chaomin WuYuanlin Song
Mar 21, 2020·Lancet·Puja MehtaUNKNOWN HLH Across Speciality Collaboration, UK
Mar 29, 2020·The Journal of Clinical Investigation·Savannah F Pedersen, Ya-Chi Ho
Mar 31, 2020·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Wen ZhangShuyang Zhang
Apr 8, 2020·Journal of Translational Medicine·Jiangnan ZhaoYi Shi
Citations
Oct 3, 2020·International Journal of Molecular Sciences·Eileen M McGowanYiguang Lin
Nov 6, 2020·British Journal of Pharmacology·Farha Naz, Mohd Arish
Nov 5, 2020·Clinical Medicine : Journal of the Royal College of Physicians of London·Deborah R Tasat, Juan S Yakisich
Feb 11, 2021·Clinical and Experimental Pharmacology & Physiology·Yuehai PanFan Chen
Apr 24, 2021·Journal of Inflammation Research·Adekunle Babajide RowaiyeMainul Haque
May 14, 2021·Drugs·Tamara Pérez-JeldresJesús Rivera-Nieves
Jul 6, 2021·Frontiers in Cell and Developmental Biology·Kid TörnquistDan Lindholm
Oct 16, 2021·Personalized Medicine·Mohd Arish, Farha Naz